Antidepressant discontinuation syndrome vs relapse comes down to two things: timing and symptom pattern. Discontinuation syndrome starts within days of stopping or reducing an antidepressant, peaks around a week, and settles if the drug is restarted. Relapse takes weeks to emerge and is the gradual return of the original depressive episode. Confuse the two and you either overtreat a self-limiting withdrawal state or undertreat a returning illness.

This distinction is a favourite exam target and a common real-world error — patients stop abruptly, feel awful, and are told their depression has come back. Below is the full framework: how each presents, the features that separate them, what the evidence says about re-challenge, and how to answer this cleanly in an MRCPsych or USMLE viva.

What is antidepressant discontinuation syndrome?

Discontinuation syndrome is a physical withdrawal state caused by the abrupt loss of a drug that the brain has adapted to. It is not dependence in the addiction sense, but the mechanism is analogous: neuroadaptive changes (serotonergic, noradrenergic, cholinergic rebound) that were compensated during treatment are suddenly unopposed when the drug goes.

Key features you should be able to reel off:

  • Onset is fast. Symptoms begin 1–3 days after stopping or missing doses, worst around days 3–5, and typically resolve within 1–2 weeks — faster for shorter half-life drugs.
  • Half-life determines severity. Paroxetine and venlafaxine (short half-lives, potent transporter effects) produce the most severe syndromes. Fluoxetine's active metabolite norfluoxetine has a half-life of 4–16 days, so it effectively tapers itself — discontinuation is rare.
  • The symptom list is somatic and affective, not cognitive. Dizziness ("brain zaps" or electric-shock sensations), nausea, flu-like malaise, insomnia, vivid dreams, irritability, and a quickly-returning anxiety or low mood. Psychomotor retardation, guilty worthlessness, and appetite change typical of a depressive episode are much less prominent.
  • The trajectory is improving. Symptoms peak early then improve, even without treatment.

NICE guidance on medicines adherence explicitly advises offering a slower taper or a longer-half-life alternative when discontinuation symptoms are a concern, rather than stopping abruptly.

Antidepressant discontinuation syndrome vs relapse: the comparison

This is the table to memorise. In an exam, anchor your answer on timing first, then symptom pattern — those two rows resolve most scenarios.

Feature Discontinuation syndrome Relapse of depression
Timing after stopping Within 1–3 days; worst by day 5 Usually 2–6 weeks or later
Course Peaks early, then improves over 1–2 weeks Gradually deepens, persists
Symptom pattern Somatic: dizziness, brain zaps, nausea, flu-like aches, insomnia, irritability Core mood syndrome: anhedonia, worthlessness, guilt, psychomotor change, appetite/weight change
Best differentiator Temporal link to dose change + somatic symptoms Persistence of full syndrome beyond 2 weeks despite no dose change
Re-challenge test Resolves within days of restarting the same drug No rapid improvement on restarting; may need dose change or switch
Management Restart same drug, resume slow taper (or switch to fluoxetine taper) Treat as returning episode: optimise dose, switch class, or add psychological therapy
Typical duration Days to ~2 weeks Weeks to months without treatment

One nuance worth a sentence in any written answer: discontinuation can unmask relapse. A patient who stops after a stable recovery may experience both — withdrawal in week 1, and a true relapse emerging later. The temporal map separates them.

Why do patients stop antidepressants abruptly?

Understanding the trigger helps you take the history. Common reasons, in practice and in exam vignettes:

  • Side effects — sexual dysfunction, weight gain, emotional blunting. The patient quietly stops rather than raise an embarrassing topic.
  • Pregnancy or planned conception — abrupt cessation after a positive test, often without discussing options with a prescriber.
  • Pre-operative instructions — "stop all your medicines before surgery" misapplied to an antidepressant that should continue.
  • Feeling better — the classic: "I don't need these anymore."
  • Running out / pharmacy gaps — particularly with short prescriptions or holiday supply issues.

Always ask directly about missed doses in the last fortnight. Patients rarely volunteer "I stopped your prescription" — they report that "the tablets aren't working."

Exam trap

A patient stops sertraline one week ago and returns with dizziness, insomnia and anxiety. If you accept "my depression is back" at face value, you increase the dose — which makes discontinuation worse until steady state returns, and tells the examiner you missed the timeline. Ask two questions: when did you last take the tablet and what started first, the dizziness or the low mood. Discontinuation can look exactly like worsening anxiety, especially in a patient whose original presentation was anxious depression.

How to make the call in clinic

Work through four steps and document each one:

  1. Establish the timeline. Exact date of last full dose or dose reduction, and any missed days in the preceding fortnight. Discontinuation within 1–3 days of that date is close to diagnostic.
  2. Map the symptom order. Somatic symptoms first (dizziness, zaps, nausea) followed by mood change suggests withdrawal. The core cognitive-affective syndrome returning first suggests relapse.
  3. Apply the re-challenge test when uncertain. Restarting the same drug at the previous effective dose producing clear improvement within 3–7 days supports discontinuation. Caution: if the original episode was severe or the gap has been long, relapse can follow regardless.
  4. Look for the episode, not just the symptoms. Worthlessness, guilt, psychomotor change, anhedonia persisting beyond two weeks after the withdrawal window has closed points to relapse.

If symptoms began weeks after stopping and are dominated by low mood rather than somatic complaints, treat it as relapse — but note in your answer that both can coexist, and withdrawal is still treated first because it resolves quickly once the drug is restarted.

Tapering: how to prevent discontinuation syndrome

Prevention beats differentiation. Practical points that carry marks:

  • Slow the tail. For short half-life drugs (paroxetine, venlafaxine IR), reductions should be small and spaced — commonly 10–25% of the current dose at intervals of 1–2 weeks, slower still below 20 mg where receptor occupancy changes steeply.
  • Use fluoxetine as a taper tool. Switching to fluoxetine (then stopping) leverages its long half-life to create a self-taper — a well-established strategy, particularly after venlafaxine or paroxetine.
  • Talk about it in advance. Patients who expect possible symptoms are far less likely to interpret them as relapse and self-manage badly.
  • Check the indication first. After a first episode of moderate depression treated for at least 6–12 months, a planned taper is reasonable; after recurrent or severe episodes, continuing treatment is usually the right call. NICE recommends reviewing the need for continued treatment at 6–12 months for moderate-to-severe depression.

Spaced-repetition practice makes this framework stick for exams — Preppsy's spaced-repetition flashcards cover discontinuation schedules and differentials in the pharmacology curriculum.

Frequently asked questions

How do you tell if it's antidepressant discontinuation syndrome or depression relapse?

Anchor on timing and symptom pattern. Discontinuation starts within 1–3 days of stopping or reducing the dose, peaks by day 5, features somatic symptoms (dizziness, brain zaps, nausea, insomnia, irritability), and settles within one to two weeks — resolving faster if the drug is restarted. Relapse emerges two to six weeks later, follows the original cognitive-affective pattern (worthlessness, anhedonia, guilt, psychomotor change), and persists. When uncertain, restarting the previous dose and seeing clear improvement within days supports discontinuation.

How long does discontinuation syndrome last after stopping an antidepressant?

Typically one to two weeks from onset, with the worst period around days 3–5. Duration tracks the drug's half-life: paroxetine and venlafaxine symptoms can persist for one to two weeks, while fluoxetine rarely causes discontinuation syndrome at all because norfluoxetine's long half-life tapers the exposure gradually. Symptoms that continue beyond two weeks warrant re-evaluating for relapse or another cause rather than assuming withdrawal.

Which antidepressants cause the worst discontinuation symptoms?

The short half-life, potent reuptake-inhibiting drugs — paroxetine and venlafaxine (including duloxetine) — produce the most severe syndromes, followed by other SSRIs such as sertraline and citalopram. MAOIs also produce a distinct discontinuation state. Fluoxetine has the mildest profile because its active metabolite provides a built-in taper. TCAs are intermediate, roughly proportional to their half-lives.

Should you restart the antidepressant if discontinuation syndrome is suspected?

Yes — restarting the same drug at the previous effective dose is both diagnostic and therapeutic: clear improvement within several days supports discontinuation and relieves symptoms. Then resume a slower taper, optionally switching to fluoxetine to self-taper off. If the syndrome was severe, or the original episode was recurrent or psychotic, also reassess whether indefinite treatment is indicated rather than a second attempt at withdrawal.

Key takeaways

  • Timing is the first question: symptoms within days of a dose change = discontinuation; weeks later = relapse.
  • Somatic vs cognitive-affective: brain zaps, dizziness and flu-like symptoms point to withdrawal; worthlessness, guilt and psychomotor change point to relapse.
  • Half-life predicts severity: paroxetine and venlafaxine are worst; fluoxetine essentially self-tapers.
  • Re-challenge is the tiebreaker: improvement within days of restarting supports discontinuation.
  • Prevention: slow tapers (10–25% steps), a fluoxetine tail, and an advance conversation about expected symptoms.
  • Both can occur together — treat the withdrawal first, then reassess the mood state once it settles.

Master differentials like this one alongside our MRCPsych exam preparation, where timeline-based reasoning is tested across psychopharmacology, mood disorders and clinical vignettes.

Cover image: “Discontinuation vs Relapse (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.